Novel and emerging treatments for major depression

Steven Marwaha, Edward Palmer, Trisha Suppes, Emily Cons, Allan H Young, Rachel Upthegrove*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

507 Downloads (Pure)

Abstract

Depression is common, costly, debilitating, and associated with increased risk of suicide. It is one of the leading global public health problems. Although existing available pharmacological treatments can be effective, their onset of action can take up to 6 weeks, side-effects are common, and recovery can require treatment with multiple different agents. Although psychosocial interventions might also be recommended, more effective treatments than those currently available are needed for people with moderate or severe depression. In the past 10 years, treatment trials have developed and tested many new targeted interventions. In this Review, we assess novel and emerging biological treatments for major depressive disorder, evaluate their putative brain and body mechanisms, and highlight how close each might be to clinical use.

Original languageEnglish
Pages (from-to)141-153
Number of pages13
JournalThe Lancet
Volume401
Issue number10371
Early online date16 Dec 2022
DOIs
Publication statusPublished - 14 Jan 2023

Bibliographical note

Copyright © 2022 Elsevier Ltd. All rights reserved.

Fingerprint

Dive into the research topics of 'Novel and emerging treatments for major depression'. Together they form a unique fingerprint.

Cite this